Cyclin D1 in mammary carcinoma

Journal of Pathology

Volumn 181, Issue 3, 1997, Pages 267-269

  Barnes, Diana M ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Cell cycle associated protein; Cyclin D1; Hormone responsive; Oncogene; Tamoxifen

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CARCINOMA; CELL CYCLE; FEMALE; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYCLIN D1; CYCLINS; FEMALE; HUMANS; MICE; NEOPLASM PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0030980877     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X     Document Type: Review

References (31)

1. Betticher DC. Cyclin D1, another molecule of the year? Ann Oncol 1996; 7: 223-225.
2. Bates S, Peters G. Cyclin D1 as a cellular proto-oncogene. Cancer Biol 1995; 6: 73-82.
3. Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 1995; 15: 2600-2611.
4. Strauss M, Lukas J, Barter KJ. Unrestricted cell cycling and cancer. Nature Med 1995; 1: 1245-1246.
5. Dou Q-P, Pardee AB, Keyomarsi K, Steeg P. Cyclin E - a better prognosticmarker for breast cancer than cyclin D1? Nature Med 1996; 2: 254.
6. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
7. Draetta GF. Mammalian G1 cyclins. Cell Biol 1994; 6: 842-846.
8. Fantl V, Brookes S, Smith R, et al. Characterization of the proto-oncogene int-2 and its potential for the diagnosis of human breast cancers. In: Furth M, Grieves M, eds. Molecular Diagnostics of Human Cancer (Cancer Cells 7). 1989; 283-287.
9. Schuuring E. Verhoeven E, van Tinteren H, et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients wiih operable breast cancer. Cancer Res 1992; 52: 5229-5234.
10. Gillett C, Fantl V, Fisher C, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817.
11. Sewing A, Burger C, Brusselbach S, Schalk C, Lucibello FC, Muller R. Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cyclic AMP. J Cell Sci 1993; 104: 545-554.
12. Musgrove EA, Hamilton JA, Lee CSL. Sweeny KJE, Watts CKW. Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993; 13: 3577-3587.
13. Pusch O, Soucek T, Wawra E, Hengstschlager-Ottnad E, Bernaschek G, Hengstschlager M. Specific transformation abolishes cyclin D1 fluctuation throughout the cell cycle. FEBS Lett 1996; 385: 143-148.
14. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumour types. Science 1994; 264: 436-140.
15. Zetterberg A, Larsson O, Wiman KG. What is the restriction point? Cell Biol 1995; 7: 835-842.
16. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713.
17. Atadja P, Wong H, Veillete C, Riabowol K. Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res 1995; 217: 205-216.
18. Musgrove E, Lee CSL, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 1994; 91: 8022-8026.
19. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994; 57: 353-361.
20. Lovec H, Sewing A, Lucibello FC, Muller R, Moroy T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle and malignant transformation. Oncogene 1994; 9: 323-326.
21. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994; 13: 2124-2130.
22. Wang TC, Cardiff RD, Zukerburg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-671.
23. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995; 82: 621-630.
24. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995; 9: 2364-2372.
25. Weinstat-Saslow D, Merino MJ, Manrow RE, el al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions, Nuture Med 1995; 1: 1257-1260.
26. Gillett C, Smith P, Gregory W, el al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer (Pred Oncol) 1996; 69: 92-99.
27. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995; 11: 885-891.
28. Michalides R, Hageman P, van Tinteren H, et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996; 73: 728-734.
29. Bartkova J, Lukas J, Strauss M, Bartek J. Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 1994; 172: 237-245.
30. Nielsen NH, Emdin SO, Landberg G. Deregulation of G1 cyclins and pRb alterations in estrogen receptor negative breast cancer with poor prognosis. Proc AACR 1996; 37: 28.
31. Watts CKW, Brady A, Sarcevic B, de Fazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995; 9: 1804-1813.